Vnitr Lek 2015, 61(5):470-474

Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF

Jiří Vítovec1,*, Jindřich ©pinar2, Lenka ©pinarová1
1 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny Brno, přednostka prof. MUDr. Lenka ©pinarová, CSc., FESC
2 Interní kardiologická klinika LF MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC

An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial, ACE inhibitors/angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans), along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin proved ineffective; on the other hand, the new dual inhibitor valsartan + neprilysin LCZ 696 is a new and promising therapeutic agent for future treatment of chronic heart failure.

Keywords: ACE inhibitors; aliskiren; angiotensin receptor blockers; chronic heart failure; LCZ 696; mineralocorticoid receptor antagonists; omapatrilat

Received: February 27, 2015; Accepted: April 8, 2015; Published: May 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J, ©pinarová L. Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF. Vnitr Lek. 2015;61(5):470-474.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Failure 2011; 13(9): 929-936. Go to original source... Go to PubMed...
    2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429-1435. Go to original source... Go to PubMed...
    3. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302. Go to original source... Go to PubMed...
    4. Cohn JN, Johnson G, Zeische S et al. A comparsion of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325(5): 303-310. Go to original source... Go to PubMed...
    5. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10): 685-691. Erratum in N Engl J Med 1992; 327(24): 1768. Go to original source... Go to PubMed...
    6. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparsion. Eur Heart J 1998; 19(3): 481-489. Go to original source... Go to PubMed...
    7. Packer M, Poole-Wilson PA, Armstrong PW et al. ATLAS Study Group. The Assessment of Treatment with Lisinopril and Survival. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100(23): 2312-2318. Go to original source... Go to PubMed...
    8. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112(16): 2426-2435. Go to original source... Go to PubMed...
    9. Cleland JGF, Tendera M, Adamus J et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338-2345. Go to original source... Go to PubMed...
    10. Pitt B, Poole-Wilson PA, Segal R et al. ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582-1587. Go to original source... Go to PubMed...
    11. Cohn JN, Tognoni GA. Valsartan Heart Failure Trial Investigators, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med 2001; 345(23): 1667-1675. Go to original source... Go to PubMed...
    12. Pfeffer MA, Swedberger K, Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-766. Go to original source... Go to PubMed...
    13. Massie BM, Carson PE, McMurray JJV et al. I-PRESERVE Investigators. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med 2008; 359(23): 2456-2467. Go to original source... Go to PubMed...
    14. Konstam MA, Neaton JD, Dickstein K et al. HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374(9704): 1840-1848. Go to original source... Go to PubMed...
    15. Pitt B, Zannad F, Remme WJ et al. Randomized Aldactone Evaluation Study Investigators. The effects of Spirolacton on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709-717. Go to original source... Go to PubMed...
    16. Zannad F, McMurray JJ, Krum H et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11-21. Go to original source... Go to PubMed...
    17. Pitt B, Pfeffer MA, Assmann FA et al. TOPCAT Investigators. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014; 370(15): 1383-1392. Go to original source... Go to PubMed...
    18. Gheorghiade M, Böhm M, Greene SJ et al. ASTRONAUT Investigators and Coordinators. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA 2013; 309(11): 1125-1135. Go to original source... Go to PubMed...
    19. Packer M, Califf RM, Konstam MA et al. OVERTURE Study Group. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106(8): 920-926. Go to original source... Go to PubMed...
    20. McMurray JJV, Packer M, Desai AS et al. PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014; 371(11): 993-1004. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.